Neumora Therapeutics, Inc. (NMRA): R&D Expense
$176.06M
Year ended 2025-12-31
$153.07M
Trailing 12 months to 2026-06-30
+24.3%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $176.06M | -12.4% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $200.93M | +40.8% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $142.72M | +55.6% | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | $91.75M | n/a | 2025-03-03, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $176.06M | -12.4% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $89.95M | -54.9% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Inhibikase Therapeutics, Inc. (IKT) | 2025-12-31 | $29.79M | +73.1% |
| Instil Bio, Inc. (TIL) | 2025-12-31 | $24.74M | +109.0% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $109.44M | -15.9% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $42.63M | +34.5% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $166.42M | -34.0% |
| SAB Biotherapeutics, Inc. (SABS) | 2025-12-31 | $34.35M | +13.6% |
Compare NMRA, EDIT, VXRT, IKT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗